10-Q: Exelixis Reports Strong Q3 Growth, Advances Pipeline

Exelixis, an oncology company, reported significant revenue and net income growth in Q3 2025, driven by strong CABOMETYX sales and positive clinical trial results for zanzalintinib.

Summary

• Net product revenues for Q3 2025 increased by 14% to $542.9 million, and by 22% to $1,576.2 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Total revenues for Q3 2025 grew 11% to $597.8 million, and 7% to $1,721.5 million for the nine months ended September 30, 2025.
• Net income for Q3 2025 surged 64% to $193.6 million, with diluted EPS of $0.69, compared to $118.0 million and $0.40 diluted EPS in Q3 2024.
• For the nine months ended September 30, 2025, net income increased 41% to $538.0 million, with diluted EPS of $1.90.
• Research and development expenses decreased by 11% in Q3 2025 to $199.2 million, and by 8% for the nine months to $611.8 million, primarily due to lower license and collaboration costs and clinical trial expenses for certain programs.
• Selling, general and administrative expenses increased by 11% in Q3 2025 to $123.7 million, and by 11% for the nine months to $395.7 million.
• The company initiated a corporate reorganization plan (2025 Plan) in Q3 2025, incurring $19.8 million in restructuring expenses, primarily for severance and employee-related costs.
• Exelixis announced positive top-line results from the STELLAR-303 pivotal trial for zanzalintinib in combination with atezolizumab in metastatic colorectal cancer, showing a statistically significant improvement in overall survival.
• The company intends to submit a New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer in the U.S. by the end of 2025.
• CABOMETYX received FDA approval in March 2025 and European Commission, Brazil, and Australia approvals in July 2025 for previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumors.
• The Board of Directors authorized an additional $750.0 million stock repurchase program in October 2025, extending through December 31, 2026, bringing total authorizations to $1.75 billion since August 2024.
• As of September 30, 2025, $104.7 million remained available for future stock repurchases under the previously authorized programs.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant increases in net product revenues and net income. The positive pivotal trial results for zanzalintinib and its impending NDA submission represent a major pipeline advancement. While collaboration revenues decreased due to milestone timing, and cash was used for share repurchases, the overall operational strength, strategic pipeline progress, and commitment to shareholder returns through expanded buyback programs indicate a very positive outlook.

Positives

• Net product revenues increased by 14% in Q3 2025 and 22% for the nine months, driven by strong demand for CABOMETYX, particularly in combination with nivolumab for advanced RCC and for previously treated advanced NET.
• Net income saw substantial growth, increasing 64% in Q3 2025 and 41% for the nine months, demonstrating improved profitability.
• Diluted EPS increased significantly by 72.5% in Q3 2025 and 48.4% for the nine months.
• Positive top-line results from the STELLAR-303 pivotal trial for zanzalintinib in metastatic colorectal cancer, showing a statistically significant improvement in overall survival, pave the way for a potential NDA submission by year-end 2025.
• CABOMETYX received multiple regulatory approvals for previously treated advanced neuroendocrine tumors, expanding its market reach.
• The company qualified for the small biotech exception under the Inflation Reduction Act (IRA) for cabozantinib through 2027 and for a phase-in of increased manufacturer discounts under the Medicare Part D Discount Program from 2025 to 2031, mitigating some drug pricing risks.
• Net cash provided by operating activities increased by 20% for the nine months ended September 30, 2025, indicating strong operational cash generation.
• Net cash provided by investing activities significantly improved, moving from a net use of $23.6 million in 2024 to a net provision of $323.2 million in 2025.
• The Board authorized an additional $750.0 million stock repurchase program, reflecting confidence in the company's financial health and commitment to shareholder returns.

Negatives

• Collaboration revenues decreased by 11% in Q3 2025 and a significant 53% for the nine months, primarily due to lower milestone achievements from Ipsen compared to the prior year.
• Cash, cash equivalents, and marketable securities decreased by 10% from December 31, 2024, to September 30, 2025, largely due to substantial stock repurchases.
• Net cash used in financing activities increased by 62% for the nine months, primarily due to higher payments for common stock repurchases and taxes related to equity awards.
• The company incurred $19.8 million in restructuring expenses in Q3 2025 related to a corporate reorganization and office closure.

Risks

• The continued commercial success of CABOMETYX is crucial for generating sufficient cash flow, and its market position is subject to intense competition.
• Maintaining coverage and reimbursement for CABOMETYX from private third-party and government payers is becoming increasingly difficult, both in the U.S. and internationally.
• Healthcare policymakers in the U.S. continue to pursue initiatives aimed at increasing healthcare cost burdens on pharmaceutical manufacturers and restricting drug prices.
• Potential competition from generic or other versions of marketed products, including cabozantinib (S)-malate tablets, could significantly decrease U.S. revenues from CABOMETYX.
• Ongoing ANDA litigations with MSN, Sun, and Azurity pose a risk of earlier-than-expected market entry for generic versions of CABOMETYX, despite favorable rulings in some cases.
• Research and development objectives may be impeded by challenges in scaling the organization, unanticipated delays in clinical testing, and inherent risks associated with drug discovery operations.
• Uncertainty exists regarding the timing and impact of U.S. administration proposals to lower prescription drug costs, including potential 'most favored nation' (MFN) pricing and direct-to-consumer sales.
• The 52-week fiscal year in 2025, compared to the 53-week fiscal year in 2024, may result in a modest year-over-year impact on revenues and expenses.
• The assumptions associated with sublease income and discount rates used in impairment evaluations are subject to risks and uncertainties and could materially differ from estimates.

Future Outlook

Exelixis projects net product revenues may increase for the remainder of 2025 due to continued demand for CABOMETYX, especially following its recent FDA approval for previously treated advanced NET. Clinical trial costs are projected to decrease for the remainder of 2025, driven by lower costs associated with certain studies, while R&D expenses overall may decrease due to lower license and collaboration costs and manufacturing costs. The company expects to progress up to two new development candidates into preclinical development later in 2025 and will continue pipeline expansion initiatives. Selling, general and administrative expenses may decrease for the remainder of 2025 due to lower corporate giving and the impact of the 2025 Plan. The company anticipates sufficient cash flow to fund operations for at least 12 months and the foreseeable future, but may incur debt or raise additional equity based on market conditions or strategic considerations.

Management Comments

• We are an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care.
• We are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset zanzalintinib, currently the focus of an extensive late-stage development program.
• We plan to continue leveraging our operating cash flows to advance a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer, as well as to support ongoing company-sponsored and externally sponsored trials evaluating cabozantinib.
• Increasing the number of novel anti-cancer agents in our pipeline is essential to our overall strategy and business goals.
• We expect to progress up to two new development candidates into preclinical development later in 2025.

Industry Context

Exelixis operates in the highly competitive oncology market, where innovation in next-generation medicines and combination regimens is critical. The company's focus on tyrosine kinase inhibitors like cabozantinib and zanzalintinib aligns with a key therapeutic area in cancer treatment. Regulatory approvals for CABOMETYX in neuroendocrine tumors expand its market presence, while ongoing pipeline development, particularly for zanzalintinib, positions Exelixis to address high unmet needs in colorectal cancer and renal cell carcinoma. The industry faces increasing pressure on drug pricing and reimbursement, as evidenced by the Inflation Reduction Act (IRA) and Medicare Part D Discount Program, though Exelixis has secured some exemptions. Patent litigations are a common challenge in the pharmaceutical industry, highlighting the importance of intellectual property protection for commercial success.

Comparison to Industry Standards

• The positive overall survival results for zanzalintinib in STELLAR-303 (20% reduction in risk of death vs. regorafenib) are a strong indicator of potential clinical differentiation in the competitive metastatic colorectal cancer landscape, where regorafenib is a standard of care.
• CABOMETYX's continued demand in advanced RCC, especially in combination with nivolumab (OPDIVO from Bristol-Myers Squibb Company), demonstrates its competitive standing against other immune checkpoint inhibitors and targeted therapies in this indication.
• The company's strategy of developing novel kinase inhibitors (zanzalintinib) and exploring biotherapeutics (ADCs, bispecific antibodies) aligns with broader industry trends towards diversified oncology pipelines and precision medicine, similar to larger pharmaceutical companies like Roche (Genentech) and Merck.
• Exelixis' qualification for the small biotech exception under the IRA and the phase-in for the Part D Discount Program provides a competitive advantage compared to larger manufacturers who may face immediate and full impact from these drug pricing reforms.

Management Changes

Corporate Governance

Legal Proceedings

• MSN ANDA Litigation (MSN I): Delaware District Court ruled in January 2023 that the effective date of any FDA approval of MSN's ANDA shall not be earlier than August 14, 2026 (expiration of the 473 Patent).
• MSN ANDA Litigation (MSN II): Delaware District Court ruled in October 2024 that the effective date of any FDA approval of MSN's ANDA shall not be earlier than January 15, 2030 (expiration of the 439, 440, and 015 Patents). MSN appealed to the CAFC on November 22, 2024, and Exelixis' cross-appeal was dismissed on June 10, 2025.
• MSN ANDA Litigation (039 Patent): Filed March 19, 2025, asserting infringement of the 039 Patent (expires 2032). Consolidated with Sun and Azurity litigations, trial scheduled for November 2, 2026.
• Sun ANDA Litigation (Multiple Patents): Filed October 30, 2024, asserting infringement of several CABOMETYX patents. Consolidated with MSN and Azurity litigations, trial scheduled for November 2, 2026.
• Sun ANDA Litigation (039 Patent): Filed April 4, 2025, asserting infringement of the 039 Patent. Consolidated with MSN and Azurity litigations, trial scheduled for November 2, 2026.
• Biocon ANDA Litigation: A settlement and license agreement was entered into in July 2025, granting Biocon a license to market its generic CABOMETYX in the U.S. beginning January 1, 2031, subject to FDA approval. Litigation was terminated on September 5, 2025.
• Azurity 505(b)(2) NDA Litigation: Filed April 18, 2025, asserting infringement of several CABOMETYX patents. Consolidated with MSN and Sun litigations, trial scheduled for November 2, 2026.
• The sale of any cabozantinib (S)-malate tablets besides CABOMETYX significantly earlier than CABOMETYX's patent expiration could materially harm revenues and business operations.

Stakeholder Impact

• Shareholders: Benefit from strong financial performance, positive clinical trial results, and expanded stock repurchase programs, indicating potential for increased shareholder value.
• Employees: Impacted by the 2025 corporate reorganization plan, which includes workforce adjustments and office closure, leading to severance and employee-related costs.
• Customers (Patients/Physicians): Benefit from expanded treatment options with CABOMETYX's new approvals and the potential for zanzalintinib to address unmet needs in various cancers.
• Collaboration Partners (Ipsen, Takeda, Merck, etc.): Continued collaboration on development and commercialization of cabozantinib and zanzalintinib, with Ipsen and Takeda contributing to global development and Merck co-funding zanzalintinib trials.
• Creditors: The company's strong cash position and operating cash flow provide confidence in its ability to meet financial obligations.

Next Steps

• Submit a New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer in the U.S. by the end of 2025.
• Continue to evaluate zanzalintinib in ongoing pivotal trials, including STELLAR-304 (advanced non-clear cell RCC) with top-line results expected in H2 2026, and STELLAR-311 (advanced NET).
• Initiate additional pivotal trials evaluating zanzalintinib across a broad array of future potential indications.
• Progress up to two new development candidates into preclinical development later in 2025.
• Continue to engage in pipeline expansion initiatives through internal research, external collaborations, and in-licensing arrangements.
• Continue stock repurchases under the authorized programs, with $104.7 million remaining from the August 2024 and February 2025 authorizations, and an additional $750.0 million authorized through December 31, 2026.
• Monitor and respond to the ongoing appeal by MSN in the CAFC regarding the MSN II patent litigation.
• Proceed with the scheduled trial for the consolidated MSN, Sun, and Azurity litigations on November 2, 2026.

Key Dates

Recommendation

Exelixis demonstrates robust financial health with significant increases in net product revenues and net income, driven by the continued success of CABOMETYX. The positive pivotal trial results for zanzalintinib in metastatic colorectal cancer, leading to an anticipated NDA submission, represent a substantial de-risking and value-creation event for the pipeline. Strategic regulatory approvals for CABOMETYX further expand its market. While collaboration revenues saw a temporary dip due to milestone timing, the underlying royalty growth remains strong. The company's aggressive and expanded stock repurchase program signals strong management confidence and commitment to shareholder returns. Despite ongoing patent litigations, the company has secured favorable outcomes for key patents, pushing back generic entry dates. The combination of strong commercial performance, a promising late-stage pipeline, and shareholder-friendly capital allocation makes Exelixis a compelling 'strong buy' for investors.

Keywords

Oncology, Cancer Treatment, CABOMETYX, Zanzalintinib, SEC Filing, Biotechnology, Pharmaceuticals, Clinical Trials, Drug Development, Renal Cell Carcinoma, Hepatocellular Carcinoma, Neuroendocrine Tumors, Colorectal Cancer, Stock Repurchase, Patent Litigation, FDA Approval, 10-Q